12:00 AM
 | 
Oct 07, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Somatuline Autogel: Additional Phase III data

Last month, Ipsen reported top-line data from the Phase III ELECT trial in about 100 patients with neuroendocrine tumors associated with carcinoid syndrome showing that subcutaneous 120 mg Somatuline Autogel every 4 weeks met the primary endpoint of reducing the percentage of days that subcutaneous octreotide was required as rescue medication to control symptoms associated with carcinoid syndrome through week 16 vs. placebo (see BioCentury, Sept. 23). Ipsen markets the product as Somatuline Depot in the U.S. to treat acromegaly and in the EU as Somatuline Autogel to...

Read the full 417 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >